Trial of Ebola virus vaccine is due to start next weekBMJ 2014; 349 doi: https://doi.org/10.1136/bmj.g5562 (Published 10 September 2014) Cite this as: BMJ 2014;349:g5562
- Sophie Arie
An unprecedented international effort is afoot to accelerate normal drug trial authorisation processes so that an experimental vaccine can be given to healthcare workers on the front line of the outbreak of Ebola virus disease in west Africa.
A fast tracked, phase I clinical trial of a vaccine developed jointly by the US National Institutes of Health and the UK drug company GlaxoSmithKline began in the United States in early September, and parallel trials are planned to start in the United Kingdom in the week of 15 September and in Mali and Gambia later in September.
The World Health Organization at first insisted that the only way to control the outbreak was through traditional containment methods, but in August, as the death toll rose and after two US aid workers were given experimental treatments, it agreed that unlicensed drugs could also be used. Since then, regulatory processes for phase I clinical …